For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Depreciation | 0 | 0* | 0 | 0 |
| Research and development | 2,745,945 | 340,185.5* | 2,192,881 | 2,499,495 |
| General and administrative | 1,748,239 | 1,083,917.5* | 1,153,032 | 2,182,289 |
| Total operating expenses | 4,494,184 | 1,424,103 | 3,345,913 | 4,681,784 |
| Operating loss | -4,494,184 | -1,424,103* | -3,345,913 | -4,681,784 |
| Other income | 31,748 | 12,971* | 2,405 | 6,881 |
| Other financing costs | - | 2,106,582* | -455,549 | - |
| Realized and unrealized gain (loss) | 541 | -27.5* | -183 | 2 |
| Net loss | -4,461,895 | -3,517,741.5* | -3,799,240 | -4,674,901 |
| Deemed dividend related to warrant modification | - | 0* | 0 | 0 |
| Net loss attributable to common stockholders | - | -3,517,741.5 | -3,799,240 | -4,674,901 |
| Basic EPS | -0.64 | -3.771 | -5 | -0.17 |
| Basic Average Shares | 6,951,999 | 932,730* | 760,502 | 27,593,952 |
Genprex, Inc. (GNPX)
Genprex, Inc. (GNPX)